The U.S. is proposing major policy changes to its healthcare sector, including imposing tariffs on global manufacturers. Click to read.

AI is reshaping labs and Clever Culture’s tech is gaining Big Pharma attention as diagnostics and cleanrooms go digital. ...

Notably, the U.S.’ two primary biopharma trade groups—the Pharmaceutical Research and Manufacturers of America (PhRMA) and ...

Pharma company stocks tumbled after Donald Trump announced a plan to reduce U.S. drug prices, but regained some ground on belief the plan would be hard to implement Drug prices are expected to decline ...

While the Trump administration’s threat of pharmaceutical import tariffs and most favored nation (MFN) drug pricing has ...

A February executive order on pharmaceutical price transparency does nothing to change the incentives that keep costs opaque. But drug companies and other stakeholders would reap the benefits of such ...

Trans-Tasman drug developer Aft Pharmaceuticals is targeting lucrative niche diseases its Big Pharma rivals have ignored ...

Joining with Democratic U.S. Sen. Jeanne Shaheen of New Hampshire, Missouri’s senior GOP senator wants to end federal subsidies for drug company advertising.

The voluble billionaire discusses his mission to transform health care, why Kamala lost, the problem with Bluesky, and much ...

A low-grade litigation between drug purchasers and big pharma is breaking out. The implications for orthopedic and spine ...

Drug prices in the United States are astronomical and climbing. Many analysts blame mergers and acquisitions among ...

The "One Big Beautiful Bill Act" includes negotiation exemptions for orphan drugs approved to treat more than one rare ...